✦ LIBER ✦

Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks

✍ Scribed by Luciano Rinaldi; P. Perini; M. Calabrese; P. Gallo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone: benefits and risks in mult

✍ V. Martinelli; M. Radaelli; L. Straffi; M. Rodegher; G. Comi 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 119 KB

Autologous haematopoietic stem-cell tran

✍ E. Capello; L. Vuolo; F. Gualandi; M. T. Van Lint; L. Roccatagliata; L. Bonzano; 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 120 KB

Hemibody irradiation. An effective secon

✍ C. R. J. Singer; J. S. Tobias; F. Giles; G. N. Rudd; G. M. Blackman; J. D. M. Ri 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB

Effectiveness and safety of high-dose cy

✍ Guillermo L. Rivell; Chris Y. Brunson; Laura Milligan; Robert K. Stuart; Luciano 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

A combination therapy with mitomycin c,

✍ Katsumasa Kuroi; Akihiko Osaki; Hiroyuki Kawami; Shigeru Murakami; Tetsuya Toge 📂 Article 📅 1997 🏛 Springer Japan 🌐 English ⚖ 374 KB

Dexamethasone, etoposide, ifosfamide, an

✍ Nissim Haim; Menachem Ben-Shahar; David Faraggi; Avital Tsuri-Etzioni; Michelle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## BACKGROUND. This study analyzed the long term results of a combination of dexa-